4DMEDICAL Ltd (4DX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.446x

Based on the latest financial reports, 4DMEDICAL Ltd (4DX) has a cash flow conversion efficiency ratio of 0.446x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-12.66 Million ≈ $-8.96 Million USD) by net assets (AU$-28.40 Million ≈ $-20.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4DMEDICAL Ltd (4DX) defensive interval to measure how many days the company can operate on defensive assets alone.

4DMEDICAL Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how 4DMEDICAL Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

4DMEDICAL Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 4DMEDICAL Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Taysha Gene Therapies Inc
NASDAQ:TSHA
-0.193x
JetBlue Airways Corp
NASDAQ:JBLU
0.066x
Guangdong Fuxin Technology Co. Ltd. A
SHG:688662
0.072x
UFP Technologies Inc
NASDAQ:UFPT
0.089x
Veridis Environment Ltd
TA:VRDS
0.096x
OFG Bancorp
NYSE:OFG
0.028x
ADAMA Ltd
SHE:000553
0.036x
Wasu Media Holding Co Ltd
SHE:000156
0.026x

Annual Cash Flow Conversion Efficiency for 4DMEDICAL Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of 4DMEDICAL Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of 4DMEDICAL Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$64.24 Million
≈ $45.45 Million
AU$-34.48 Million
≈ $-24.39 Million
-0.537x 0.00%
2024-12-31 AU$64.24 Million
≈ $45.45 Million
AU$-34.48 Million
≈ $-24.39 Million
-0.537x -23.33%
2024-06-30 AU$70.93 Million
≈ $50.19 Million
AU$-30.87 Million
≈ $-21.84 Million
-0.435x 0.00%
2023-12-31 AU$70.93 Million
≈ $50.19 Million
AU$-30.87 Million
≈ $-21.84 Million
-0.435x -37.29%
2023-06-30 AU$71.46 Million
≈ $50.56 Million
AU$-22.65 Million
≈ $-16.03 Million
-0.317x 0.00%
2022-12-31 AU$71.46 Million
≈ $50.56 Million
AU$-22.65 Million
≈ $-16.03 Million
-0.317x +25.34%
2022-06-30 AU$59.51 Million
≈ $42.11 Million
AU$-25.27 Million
≈ $-17.88 Million
-0.425x 0.00%
2021-12-31 AU$59.51 Million
≈ $42.11 Million
AU$-25.27 Million
≈ $-17.88 Million
-0.425x -143.76%
2021-06-30 AU$83.36 Million
≈ $58.98 Million
AU$-14.52 Million
≈ $-10.27 Million
-0.174x 0.00%
2020-12-31 AU$83.36 Million
≈ $58.98 Million
AU$-14.52 Million
≈ $-10.27 Million
-0.174x -126.89%
2020-06-30 AU$-11.81 Million
≈ $-8.36 Million
AU$-7.65 Million
≈ $-5.41 Million
0.648x 0.00%
2019-12-31 AU$-11.81 Million
≈ $-8.36 Million
AU$-7.65 Million
≈ $-5.41 Million
0.648x +151.07%
2019-06-30 AU$4.56 Million
≈ $3.22 Million
AU$-5.78 Million
≈ $-4.09 Million
-1.269x 0.00%
2018-12-31 AU$4.56 Million
≈ $3.22 Million
AU$-5.78 Million
≈ $-4.09 Million
-1.269x -41.85%
2018-06-30 AU$3.78 Million
≈ $2.67 Million
AU$-3.38 Million
≈ $-2.39 Million
-0.894x 0.00%
2017-12-31 AU$3.78 Million
≈ $2.67 Million
AU$-3.38 Million
≈ $-2.39 Million
-0.894x -34.64%
2017-06-30 AU$3.25 Million
≈ $2.30 Million
AU$-2.16 Million
≈ $-1.53 Million
-0.664x 0.00%
2016-12-31 AU$3.25 Million
≈ $2.30 Million
AU$-2.16 Million
≈ $-1.53 Million
-0.664x +12.45%
2016-06-30 AU$926.64K
≈ $655.66K
AU$-703.00K
≈ $-497.42K
-0.759x 0.00%
2015-12-31 AU$926.64K
≈ $655.66K
AU$-703.00K
≈ $-497.42K
-0.759x -887.57%
2015-06-30 AU$532.93K
≈ $377.08K
AU$-40.94K
≈ $-28.97K
-0.077x 0.00%
2014-12-31 AU$532.93K
≈ $377.08K
AU$-40.94K
≈ $-28.97K
-0.077x --

About 4DMEDICAL Ltd

AU:4DX Australia Medical Devices
Market Cap
$1.84 Billion
AU$2.60 Billion AUD
Market Cap Rank
#6590 Global
#151 in Australia
Share Price
AU$4.54
Change (1 day)
+17.62%
52-Week Range
AU$0.23 - AU$6.80
All Time High
AU$6.80
About

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function im… Read more